 |
市场调查报告书
商品编码
1898404
In Silico药物发现市场规模、份额和成长分析（按产品、工作流程、治疗领域、最终用户和地区划分）—产业预测（2026-2033 年）Insilico Drug Discovery Market Size, Share, and Growth Analysis, By Product (Software-as-a-Service, Software), By Workflow (Pre-Clinical Tests, Discovery), By Target Therapeutic Area, By End User, By Region - Industry Forecast 2026-2033 |
||||||
2024 年全球In Silico药物发现市场规模为 32.2 亿美元，预计从 2025 年的 35.7 亿美元成长到 2033 年的 82.4 亿美元，在预测期（2026-2033 年）内复合年增长率为 11%。
由于生物资讯技术的进步，全球In Silico药物发现市场正经历显着扩张。这些技术能够促进药物标靶辨识、候选分子开发和结合特性优化。药物发现数据的快速增长，以及对生物标记识别和降低医院再入院率及医疗差错的日益重视，是推动市场成长的关键因素。此外，药物发现领域计算方法的快速发展也进一步刺激了市场需求。In Silico药物设计服务的成本效益和日益增长的接受度也对市场趋势产生了积极影响。然而，价格压力、外包以及开放原始码软体的威胁等挑战可能会在短期内抑制这一成长势头。
推动全球In Silico药物发现市场发展的因素
全球In Silico药物发现市场的成长主要得益于生物标记识别技术的进步，这些技术增强了标靶治疗的开发能力。此外，降低医院再入院率和减少医疗错误的日益重视也推动了对更有效率药物发现流程的需求。计算生物学领域计算技术的创新正在促进该领域的进一步发展。此外，In Silico药物发现技术的改进也显着促进了市场扩张，因为它能够更快、更准确地识别潜在候选药物，从而简化整个药物开发流程。这些因素共同为市场的持续成长奠定了坚实的基础。
全球In Silico药物发现市场面临的限制因素
全球In Silico药物发现市场面临一个重大限制：此技术固有的分析时间窗口极短。这些分析间隔从几纳秒到几百纳秒不等，具体取决于模拟系统的大小和复杂性以及可用的计算资源。如此短的时间窗口往往会阻碍对蛋白质折迭动力学的准确动态，并导致蛋白质构象采样不足。因此，有限的时间解析度给产生可靠且全面的资讯带来了挑战，而这些资讯对于有效的药物发现过程至关重要。
全球In Silico药物发现市场趋势
全球In Silico药物发现市场呈现出显着趋势，这主要得益于云端工具的日益普及，它彻底改变了药物研究人员进行药物发现和开发的方式。云端运算提供的柔软性和可扩展性使研究人员能够动态调整运算资源，从而加速资料分析和模型模拟。这种适应性使机构能够根据特定计划需求量身定制解决方案，提高药物开发平臺各个阶段的效率。此外，像BT的云端运算生命科学平台这样的平台提供客製化的製药应用，简化了从药物发现到商业化的流程，并支援不同团队之间的兼容性，而无需使用统一的应用程式。
目录
介绍
- 调查目标
- 调查范围
- 定义
调查方法
- 资讯收集
- 一手和二手资料方法
- 市场规模预测
- 市场假设与限制
执行摘要
- 全球市场展望
- 供需趋势分析
- 细分市场机会分析
市场动态与展望
- 市场规模
- 市场动态
- 驱动因素和机会
- 限制与挑战
- 波特分析
关键市场考察
- 关键成功因素
- 竞争程度
- 关键投资机会
- 市场生态系统
- 市场吸引力指数（2025）
- PESTEL 分析
- 总体经济指标
- 价值链分析
- 定价分析
- 监管环境
- 用例
- 技术进步
全球In Silico药物发现市场规模（按产品划分）及复合年增长率（2026-2033 年）
- SaaS（Software-as-a-Service）
- 软体
- CaaS（Consultancy-as-a-Service）
全球In Silico药物发现市场规模（按工作流程和复合年增长率划分）（2026-2033 年）
- 临床前试验
- 药物发现
- 实验室测试
全球In Silico药物发现市场规模（按治疗领域划分）及复合年增长率（2026-2033 年）
- 代谢性疾病
- HIV
- 感染疾病
- 肌肉骨骼疾病
- 精神疾病
- 神经系统疾病
- 肿瘤疾病
全球In Silico药物发现市场规模（按最终用户划分）及复合年增长率（2026-2033 年）
- CRO（受託研究机构）
- 製药和生物製药公司
- 学术研究机构
- 其他的
全球In Silico药物发现市场规模及复合年增长率（2026-2033）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
- 拉丁美洲
- 巴西
- 其他拉丁美洲
- 中东和非洲
- GCC
- 南非
- 其他中东和非洲地区
竞争资讯
- 前五大公司对比
- 主要企业的市场定位（2025 年）
- 主要市场参与者所采取的策略
- 近期市场趋势
- 公司市占率分析（2025 年）
- 主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较
主要企业简介
- Atomwise（美国）
- Insilico Medicine（香港）
- 伊克托斯（法国）
- 摇篮（美国）
- BenevolentAI（英国）
- 薛丁格（美国）
- Cloud Pharmaceuticals（美国）
- 数位（美国）
- 晶铁（中国）
- BenevolentAI（英国）
- Biovista（美国）
- Certara（美国）
- Cloud Pharmaceuticals（美国）
- 晶铁（中国）
- Atomwise（美国）
- Exscientia（英国）
- Insilico Medicine（香港）
- 伊克托斯（法国）
- 摇篮（美国）
结论与建议
Global Insilico Drug Discovery Market size was valued at USD 3.22 Billion in 2024 and is poised to grow from USD 3.57 Billion in 2025 to USD 8.24 Billion by 2033, growing at a CAGR of 11% during the forecast period (2026-2033).
The global in-silico drug discovery market is witnessing significant expansion driven by advancements in bioinformatics technologies, which facilitate the identification of drug targets, development of candidate molecules, and optimization of binding properties. The surge in drug discovery data is a primary catalyst for market growth, alongside the increasing emphasis on biomarker identification and efforts to minimize readmission rates and medical errors. Additionally, rapid enhancements in computational methodologies within drug discovery are further propelling market demand. The cost-effectiveness and growing acceptance of in-silico drug design services also contribute positively to market trends. However, challenges such as pricing pressures, outsourcing, and the threat posed by open-source software could moderate this growth trajectory in the foreseeable future.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insilico Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Insilico Drug Discovery Market Segments Analysis
Global Insilico Drug Discovery Market is segmented by Product, Workflow, Target Therapeutic Area, End User and region. Based on Product, the market is segmented into Software-as-a-Service, Software and Consultancy-as-a-Service. Based on Workflow, the market is segmented into Pre-Clinical Tests, Discovery and Clinical Tests. Based on Target Therapeutic Area, the market is segmented into Metabolic disorders, HIV, Infectious diseases, Musculoskeletal disorders, Mental disorders, Neurological disorders and Oncological disorders. Based on End User, the market is segmented into Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Insilico Drug Discovery Market
The growth of the global in-silico drug discovery market is largely driven by advancements in biomarker identification, which enhance the ability to develop targeted therapies. Additionally, the emphasis on reducing readmission rates and minimizing medical errors is propelling demand for more efficient drug discovery processes. Innovations in computational technology within the realm of computational biology are further accelerating progress. Furthermore, enhancements in in-silico drug discovery techniques contribute significantly to the market's expansion, enabling faster and more accurate identification of potential drug candidates while streamlining the overall drug development process. Together, these factors create a robust foundation for the market's continued growth.
Restraints in the Global Insilico Drug Discovery Market
The Global In-Silico Drug Discovery market faces a significant limitation due to the inherently short duration of analysis periods associated with this technology. These analysis intervals can vary from a few nanoseconds to several hundred nanoseconds, contingent upon the size and complexity of the simulated systems as well as the computational resources available. This brevity often hampers the ability to accurately predict protein folding dynamics, leading to insufficient sampling of protein conformations. Consequently, the limitations in temporal resolution pose challenges in generating reliable and comprehensive insights necessary for effective drug discovery processes.
Market Trends of the Global Insilico Drug Discovery Market
The Global In-Silico Drug Discovery market is witnessing a significant trend driven by the rising adoption of cloud-based tools, revolutionizing how pharmaceutical researchers approach drug development. The flexibility and scalability afforded by cloud computing enable researchers to adjust their computing resources dynamically, facilitating accelerated data analysis and model simulations. This adaptability allows organizations to tailor solutions to meet specific project needs, enhancing efficiency across various stages of the drug development pipeline. Furthermore, platforms like BT's Cloud Compute life sciences offer tailored pharmaceutical applications that streamline processes from discovery to commercialization, supporting compatibility across diverse teams without necessitating uniform application usage.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Landscape
- Case Studies
- Technological Advancement
Global Insilico Drug Discovery Market Size by Product & CAGR (2026-2033)
- Market Overview
- Software-as-a-Service
- Software
- Consultancy-as-a-Service
Global Insilico Drug Discovery Market Size by Workflow & CAGR (2026-2033)
- Market Overview
- Pre-Clinical Tests
- Discovery
- Clinical Tests
Global Insilico Drug Discovery Market Size by Target Therapeutic Area & CAGR (2026-2033)
- Market Overview
- Metabolic disorders
- HIV
- Infectious diseases
- Musculoskeletal disorders
- Mental disorders
- Neurological disorders
- Oncological disorders
Global Insilico Drug Discovery Market Size by End User & CAGR (2026-2033)
- Market Overview
- Contract Research Organizations
- Pharmaceutical and Biopharmaceutical Companies
- Academic and Research Institutes
- Others
Global Insilico Drug Discovery Market Size & CAGR (2026-2033)
- North America (Product, Workflow, Target Therapeutic Area, End User)
- US
- Canada
- Europe (Product, Workflow, Target Therapeutic Area, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product, Workflow, Target Therapeutic Area, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product, Workflow, Target Therapeutic Area, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Product, Workflow, Target Therapeutic Area, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Atomwise (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Insilico Medicine (Hong Kong)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Iktos (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cradle (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BenevolentAI (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Schrodinger (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cloud Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Numerate (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- XtalPi (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BenevolentAI (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biovista (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Certara (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cloud Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- XtalPi (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Atomwise (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exscientia (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Insilico Medicine (Hong Kong)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Iktos (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cradle (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
